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Abstract The SIV-infected rhesus macaque (Macaca
mulatta) is the most established model of AIDS disease
systems, providing insight into pathogenesis and a mod-
el system for testing novel vaccines. The understanding
of cellular immune responses based on the identification
and study of Major Histocompatibility Complex (MHC)
molecules, including their MHC:peptide-binding motif,
provides valuable information to decipher outcomes of
infection and vaccine efficacy. Detailed characterization
of Mamu-B*039:01, a common allele expressed in Chi-
nese rhesus macaques, revealed a unique MHC:peptide-
binding preference consisting of glycine at the second
position. Peptides containing a glycine at the second
position were shown to be antigenic from animals pos-
itive for Mamu-B*039:01. A similar motif was previ-
ously described for the D
d mouse MHC allele, but for
none of the human HLA molecules for which a motif is
known. Further investigation showed that one additional
macaque allele, present in Indian rhesus macaques,
Mamu-B*052:01,s h a r e st h i ss a m em o t i f .T h e s e“G2”
alleles were associated with the presence of specific
residues in their B pocket. Thispocketstructure was found
in 6% of macaque sequences but none of 950 human HLA
class I alleles. Evolutionary studies using the “G2” alleles
points to common ancestry for the macaque sequences, while
convergent evolution is suggested when murine and macaque
sequences are considered. This is the first detailed character-
ization of the pocket residues yielding this specific motif in
nonhuman primates and mice, revealing a new supertype
motif not present in humans.
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Rhesus macaques have been extensively used in infectious
disease research. This model provided key insights into
disease pathogenesis and allowed for the evaluation of novel
vaccine concepts. Two populations of rhesus macaques,
consisting of Indian-origin rhesus macaques and Chinese-
origin rhesus macaques, have been utilized extensively in
AIDS research and for other models of infectious diseases
(Gardner and Luciw 2008; Giraldo-Vela et al. 2008; Miller
et al. 1989; Smith et al. 1999). While these two sets of
animals appear to be indistinguishable physiologically, ge-
netic factors affecting immune responses appear to be quite
distinct. This is particularly true in terms of the Major Histo-
compatibility Complex (MHC) class I molecules, which de-
termine the repertoire of T-cell responses that an individual
can develop against Simian Immunodeficiency Virus (SIV)
and/or any other foreign pathogen (Parham 2005). Recent
studies have shown that the MHC gene regions of Indian
and Chinese macaques differ appreciably in terms of the
degree of polymorphism, the specific allelic variant, and their
functional characteristics (Solomon et al. 2010; Southwood et
al. 2011; Wiseman et al. 2009).
In previous studies, we have investigated the MHC:pep-
tide-binding repertoire of several MHC class I and II mole-
cules in Indian-origin rhesus macaques, such as Mamu-
A*01 (Allen et al. 1998), -B*17 (Mothe et al. 2002), -
B*01 (Loffredo et al. 2005), -DRB1*0406, and -
DRB*w201 (Dzuris et al. 2001) among others (Dzuris et
al. 2000; Giraldo-Vela et al. 2008; Loffredo et al. 2008;
Loffredo et al. 2007;L o f f r e d oe ta l .2004;R e e de ta l .
2011; Sette et al. 2005). While Chinese rhesus macaques
are of value as animal models for AIDS vaccine develop-
ment and for other pathogens, their full potential has not
been realized due to missing functional MHC and genetic
information.
We have recently started to define peptide-binding motifs
for common Chinese macaque MHC class I molecules and
to date have elucidated detailed quantitative motifs for three
alleles: Mamu-A1*026:01, Mamu-B*083:01 (Southwood et
al. 2011), and Mamu-A1*022:01 (Solomon et al. 2010).
Interestingly, we found that all of these molecules are asso-
ciated with motifs that are overlapping with well-known
HLA supermotifs. Specifically, Mamu-A1*026:01 shares a
high degree of cross-reactivity with the HLA-A2 supertype
allele HLA-A*02:02, as well as -A*02:01 and -A*02:03,
while Mamu-B*083:01 is highly cross-reactive with HLA-
A3 supertype alleles HLA-A*31:01, -A*03:01, and -
A*68:01 (Southwood et al. 2011). Additionally, Mamu-
A*022:01 is highly cross-reactive with the HLA-B7 super-
type alleles B*07:02 and B*35:01 (Solomon et al. 2010).
The HLA-B7, -A3, and -A2 supertypes are the three most
abundant supertypes in the human population, each present
with a phenotypic frequency of greater than 40%, averaged
across various ethnic groups (Sette and Sidney 1998; Sette
and Sidney 1999).
To fully realize the potential of Chinese-origin macaques
in infectious disease research, further investigation and char-
acterization of the most commonly expressed MHC alleles
is necessary. This will facilitate accurate assessment of
cellular immunity and immune correlates of protection. In
the present set of experiments, we focused on a high-
frequency allele in Chinese rhesus macaques, Mamu-
B*039:01, which is present in 5.8% of Chinese rhesus
macaques (Solomon et al. 2010). We sought to character-
ize Mamu-B*039:01 by determining its specific MHC:
peptide-binding motif. We were surprised to find that its
motif consisted of a preference for glycine (G) at posi-
tion 2. Analysis of published literature revealed that
only the murine class I molecule H-2 D
d has been
reported to share this specificity. The analysis of known
Mamu and HLA sequences resulted in the definition of
structural characteristics associated with the preference
for glycine in position 2 and led us to discover another
macaque allele that we subsequently demonstrated to be
associated with similar peptide-binding specificity.
Structural and phylogenetic analysis suggested that this
MHC motif is not found among HLA alleles. Hence, herein
we propose a new supertype motif present in macaques and
mice, but not in humans.
Materials and methods
Creation of stable Mamu-B*039:01 and Mamu-B*052:01
transfectant cell lines
To produce secreted Mamu molecules in the context of
endogenous ligand identification, α-chain complementa-
ry DNAs (cDNAs) of Ch-Mamu-B*039:01 and In-
Mamu-B*052:01 were modified at the 3' end by PCR
mutagenesis to delete codons 5–7 encoding the trans-
membrane and cytoplasmic domains and to add a 30 bp
tail encoding the ten amino acid rat very low-density
lipoprotein receptor (VLDLr), SVVSTDDDLA, for pu-
rification purposes (Hickman et al. 2000). sMHC–
VLDLr were cloned into the mammalian expression
vector pcDNA3.1 (Invitrogen). The MHC class I-
deficient EBV-transformed B-lymphoblastoid cell line
721.221 cells were transfected with sMHCs Mamu-
B*39TVLDLr and Mamu-B*52TVLDLr by electroporation.
After48hofincubation,thecellswereplatedin96-wellplates
(Falcon) in RPMI 1640 containing the antibiotic Geneticin.
Transfectants were tested for the production of sMHC mole-
cules by a VLDLr-specific ELISA (Hawkins et al. 2008).
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Separately, approximately 25 mg of Mamu-B*39TVLDLr
and Mamu-B*52TVLDLr molecules from the 721.221 cell
line were purified over an affinity column composed of anti-
VLDLr antibody (ATCC clone CRL-2197) coupled to
CNBr-activated Sepharose 4B (GE Healthcare, Piscataway,
NJ). sMHC molecules were then eluted in 0.2 N acetic acid,
brought up to 10% acetic acid, and heated to 76°C for
10 min. Peptides were separated from heavy and light chains
by ultra-filtration in a stirred cell with a 3-kDa molecular
weight cutoff cellulose membrane (Millipore, Bedford,
MA). The peptide batch was flash frozen and lyophilized.
The peptides were then reconstituted in 10% acetic acid.
Following isolation, 10% of the peptide pool was sub-
jected to 14 rounds of N-terminal sequencing by Edman
degradation. A motif was generated by calculating the fold
increase of each amino acid over the prior round. A hierar-
chy was then determined based on the amino acid compo-
sition at each position (Falk et al. 1991).
Peptides were reverse-phase HPLC fractionated using a
Jupiter Proteo C12 column (Phenomenex, Torrance, CA) on
a Paradigm MG4 system (Michrom Bioresources, Auburn,
CA). A standard CH3CN gradient was employed to generate
approximately 40 peptide-containing fractions. UV absorp-
tion was monitored at 215 nm. Peptide fractions were concen-
trated to dryness and reconstituted in 20 μl of nanospray
buffercomposedof50%methanol,50%H20,and0.5%acetic
acid. Nano-electrospray capillaries (Proxeon, Denmark) were
loaded with 1 μl of each peptide fraction and infused at
1,100 Von a Q-Star Elite quadrupole mass spectrometer with
a time of flight detector (Applied Biosystems, Foster City,
CA). Ion maps were generated for each fraction in a mass
range of 300-1,200 amu. Using independent data acquisition
for selection, ions (putative peptides) were fragmented by
tandem mass spectrometry (MS/MS). An amino acid se-
quence was assigned using the publicly available, web-based
MASCOT(MatrixScienceLtd.,London,UK)and/ordenovo
sequencing.
Positional scanning combinatorial library and peptide
synthesis
Positional scanning combinatorial libraries (PSCLs) were
synthesized as previously described (Pinilla et al. 1999). In
the PCSL, each pool in the library contains randomized 9-
mer peptides with one fixed residue at a single position.
With each of the 20 naturally occurring residues represented
at each position along a 9-mer backbone, the entire library
consisted of 180 peptide mixtures.
Peptides utilized in screening studies were purchased as
crude or purified material from Mimotopes (Minneapolis,
MN, USA/Clayton, Victoria, Australia), Pepscan Systems
B. V. (Lelystad, Netherlands), A&A Labs (San Diego, CA,
USA), Genescript Corporation (Piscataway, NJ, USA), or
the Biotechnology Center at the University of Wisconsin-
Madison (Madison, WI, USA). Peptides synthesized for use
as radiolabeled ligands were synthesized by A&A Labs and
purified to >95% homogeneity by reverse-phase HPLC.
Peptide purity was determined with analytical reverse-
phase HPLC and amino acid analysis, sequencing, and/or
mass spectrometry. Peptides were radiolabeled utilizing the
chloramine T method (Sidney et al. 2001). Lyophilized
peptides were resuspended at 20 mg/ml in 100% DMSO,
then diluted to required concentrations in PBS+0.05% (v/v)
nonidet P40 (Fluka Biochemika, Buchs, Switzerland). SIV
peptide sequences were derived from the SIVmac239 se-
quence, Genbank accession M33262 (Kestler et al. 1990).
MHC purification and peptide-binding assays
Mamu class I MHC purification was performed by affinity
chromatography using the W6/32 and/or B123.2 class I
antibodies, as previously described (Allen et al. 2001;
Loffredo et al. 2009; Sidney et al. 2005). Protein purity,
concentration, and depletion efficiency steps were moni-
tored by SDS-PAGE.
Quantitative assays for peptide binding to detergent-
solubilized MHC class I molecules were based on the inhi-
bition of binding of a high affinity radiolabeled standard
probe peptide and performed as detailed in prior studies
(Loffredo et al. 2009; Schneidewind et al. 2008; Sidney et
al. 2001; Sidney et al. 2005). Peptides were tested at six
different concentrations covering a 100,000-fold dose range
in three or more independent assays. Control wells to mea-
sure nonspecific (background) binding were also included.
In each experiment, a titration of the unlabeled version of
the radiolabeled probe was also tested as a positive control
for inhibition.
The radiolabeled peptides utilized for the Mamu-
B*039:01 and Mamu-B*052:01 assays were 3422.03 (se-
quence YGFSDPLTF) and 3289.0028 (VGNVYVKF), re-
spectively, representing sequences identified by Edman
degradation and mass spectrometry analysis (described
above). For each peptide, the concentration of peptide yield-
ing 50% inhibition of the binding of the radiolabeled probe
peptide (IC50) was calculated. Under the conditions used,
where [radiolabeled probe] < [MHC] and IC50 ≥ [MHC], the
measured IC50 values are reasonable approximations of the
true Kd values (Gulukota et al. 1997; Sette et al. 1994).
PCR-SSP
Peripheral blood mononuclear cells (PBMCs) from two
SIVmac239 challenged and infected Chinese rhesus maca-
ques were supplied by Bioqual (Rockville, MD). The total
Immunogenetics (2012) 64:421–434 423RNA was extracted from ten million PBMCs using the
Qiagen Qiashredder tissue homogenizer and the AllPrep
DNA/RNA Mini Kit catalog #80204 and the manufac-
turer’s protocol (Qiagen, Valencia, CA, USA). First-
strand cDNA was synthesized for each sample from
50 ng of RNA using the Super Script III First-Strand
Synthesis for RT-PCR kit catalog #18080-51 (Invitro-
gen, Carlsbad, CA, USA). The cDNA was then used in
MHC typing utilizing sequence-specific primers in po-
lymerase chain reaction (PCR-SSP) as previously de-
scribed (Karl et al. 2008). The presence of a Mamu-
B*039:01 specific 500 bp in length product was visualized
for both animals by agarose gel electrophoresis.
IFN-γ ELISPOT assay
We performed enzyme-linked immunosorbent spot (ELI-
SPOT) assays to assess SIV-specific T-cell responses, as
described previously (Allen et al. 2001). Briefly, 1×10
5
PBMCs were used per well in precoated ELISpot
PLUS kits
(Mabtech, Mariemont, OH) according to the manufacturer’s
instructions for the detection of IFN-γ-secreting cells. All
tests were performed in triplicate using individual peptides
at 10 μM. The positive control, Con A (Sigma-Aldrich),
was used at a final concentration of 5 μg/ml. The negative
control wells were devoid of any stimulation. The 96-well
plates were incubated for 20 h at 37°C in 5% CO2. Wells
were imaged and counted with Zeiss KS EliSpot reader and
analyzed. Spots were counted by an automated system with
set parameters for size, intensity, and gradient. Background
(the mean of wells without peptide stimulation) levels were
subtracted from each well on the plate. Responses were
considered positive if the mean of the number of SFC was
more than 50 spots per million cells and the p≤0.05. The
level of statistical significance was determined with a Stu-
dent’s t test using the mean of triplicate values of the
response against individual peptides versus the response
against the negative control.
Bioinformatic analysis
Analysis of the PSCL data was performed as described
previously (Sidney et al. 2008). Briefly, IC50 nM values
for each mixture were standardized as a ratio to the geomet-
ric mean IC50 nM value of the entire set of 180 mixtures
and then normalized at each position so that the value
associated with optimal binding at each position corre-
sponds to 1. For each position, an average (geometric)
relative binding affinity (ARB) was calculated, and then,
the ratio of the ARB for the entire library to the ARB for
each position was derived. We have denominated this ratio,
which describes the factor by which the normalized geomet-
ric average binding affinity associated with all 20 residues at
a specified position differs from that of the average affinity
of the entire library, as the specificity factor (SF). As calcu-
lated, positions with the highest specificity will have the
highest SF value. Primary anchor positions were then de-
fined as those with an SF ≥2.4. This criterion identifies
positions where the majority of residues are associated with
significant decreases in binding capacity.
Secondary anchor designations were based on the stan-
dard deviation (SD) of residue specific values at each posi-
tion. Dominant secondary anchor positions were defined as
those where the SD was >3 and the SF <2.4, as well as
positions associated with an SD >2 if the SF is between 1.5
and 2.4. Weak secondary anchors have been defined as
positions associated with a SD in the 2.5–3 range with an
SF <1.5, or an SF in the 1.5–2.4 range with an SD <2.
For single amino acid substitution (SAAS) panels, larger
SD values are inherent comparable to PSCL, and therefore,
more stringent criteria were employed for defining primary
and secondary anchor positions. For SAAS, a primary an-
chor position is defined as one in which the SF ≥3.5.
Secondary anchor positions were defined as those where
the SD was >12 with an SF <3.5 or at positions with an
SD >10 and an SF in the 1.5–3.5 range.
To identify predicted binders, all possible 9-mer peptides
in SIVmac239 sequences were scored using the matrix
values derived from the PSCL analyses of Mamu-
B*039:01 and Mamu-B*052:01 (Sidney et al. 2008). The
final score for each peptide represents the product of the
corresponding matrix values for each peptide residue–posi-
tion pair. Peptides scoring among the top 3.0% (n0100)
were selected for binding analysis.
Phylogenetic reconstruction
We obtained a multiple sequence alignment of 266 full-
length Mamu-B nucleotide sequences from the IPD-
MHC database release 1.6.0 (Robinson et al. 2010).
The human allele HLA-B*07:02 was used as an out-
group. From the aligned MHC sequences, we deleted 51
codons encoding residues that form the binding pockets
of the MHC molecules in order to avoid binding
specificity-determining positions biasing the phylogeny.
For phylogenetic reconstruction, we used the maximum-
likelihood-based method Phyml (Guindon and Gascuel
2003) with the HKY model of nucleotide substitution
(Hasegawa et al. 1985), a maximum-likelihood estimate
of the proportion of invariable sites, four discrete
gamma-distributed substitution rate categories, and
1,000 bootstrap runs. The HKY model was selected
b a s e do nj M o d e l t e s t( P o s a d a2008). The phylogenetic
trees were visualized using SplitsTree (Huson and
Bryant 2006) and Dendroscope (Huson et al. 2007),
respectively.
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Preference for glycine in position 2 of peptides binding
to Mamu-B*039:01
We were interested in defining the MHC:peptide-binding
motif for Mamu-B*039:01 because, with a reported fre-
quency of 5.8% in the captive-bred population (Solomon
et al. 2010), it represents one of the most frequent Chinese
rhesus macaque alleles whose binding specificity has yet to
be characterized. Previous studies have demonstrated that
the elution and characterization of naturally bound ligands is
an effective method for determining the peptide-binding
specificity of class I MHC molecules (Hickman-Miller et
al. 2005; Kubo et al. 1994). Accordingly, we evaluated the
natural ligands associated with soluble Mamu-B*039:01 by
sequencing 21 different endogenously loaded Mamu-
B*039:01 peptide ligands representing six different peptide
fractions (Table 1). The majority of ligands (14 of 21; 67%)
were nine residues in length. Ligands of ten residues (n04)
were also identified. Ligands of 8, 11, and 12 residues were
only rarely found (one instance each). These observations
suggest that nonamers represent the preferred size for pep-
tide ligands bound to Mamu-B*039:01.
Next, we aligned the endogenously bound peptides and
tabulated the frequency of various amino acid residues at
each position (Fig. 1). The results indicated an overwhelm-
ing preference for glycine (G) in position 2, as demonstrated
by its presence in 20 of the 21 natural ligands (95%). At the
C-terminus, aromatic residues phenylalanine (F) and trypto-
phan (W) accounted for 62% of residues observed (13/21)
and the aliphatic residues leucine (L) and isoleucine (I)
accounted for the remaining eight (38%). This information
identifies position 2 and the C-terminus as the likely main
anchor positions for Mamu-B*039:01 binding.
To confirm that the sequenced peptides were indeed
natural ligands of B*039:01, a binding assay was developed
using purified MHC, as described in the “Materials and
methods” section. Using this assay, we were able to confirm
that the eluted ligands, the basis of the preliminary motif, do
indeed bind Mamu-B*039:01 with high affinity. Specifical-
ly, 20 of the 21 endogenous peptides identified bound with
IC50s of 50 nM or better.
Derivation of a detailed quantitative motif
The Mamu-B*039:01 binding capacity of a nonamer
PSCL was determined next. As shown in Fig. 2, the PSCL
analysis confirmed the preliminary motif defined on the
basis of the pool sequencing data. Specifically, using the
criteria outlined in the “Materials and methods” section,
position 2 and the C-terminus were identified as the primary
binding anchors, with G being dominant at position 2 and
aromatic residues F and W preferred at the C-terminus.
Table 1 Endogenous Mamu-B*039:01 ligands identified by MS/MS
sequencing analysis
Fraction Sequence Length Binding affinity
(IC50 nM)
47 RGVEKPPHL 9 1.0
52 SGYEGRVPL 9 4.8
52 KGAGTGGLGL 10 1.1
52 RGAGTGGLGL 10 4.8
57 IGVSHPLSI 9 63
57 SGFPAKVTAHW 11 1.3
57 SGKLKVPEW 9 19
57 KGFVRENVW 9 0.20
57 RGTKVILHL 9 7.1
60 AGVFVPRSF 9 0.62
60 IGYPKPALL 9 0.13
60 LGGVAVGI 8 8.0
60 KKYDVPLSW 9 1.8
68 QGFPTIKIF 9 2.5
68 KGYGLGSGISLF 12 0.45
68 VGLGPALEF 10 1.3
70 SGFWKALTF 9 0.63
70 AGIFPRLSF 9 0.49
70 AGFRALGLF 9 0.31
70 QGFLVFHSF 9 0.12
70 YGFSDPLTF 10 1.2
Fig. 1 Residue frequency summary of sequenced Mamu-B*039:01
ligands. Specific amino acids are indicated and color-coded if present
at a given position in greater than 10% of ligands identified. White bars
represent all other unspecified residues
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at the C-terminus, as well as positively charged lysine (K).
Additionally, positions 1 and 3 were identified as dominant
secondary anchors. A pictorial summary representation of
the Mamu-B*039:01 motif is shown in Fig. 3a.
Peptides with a glycine at the second position are antigenic
in Mamu-B*039:01 animals
To validate the proposed motif at the functional level, we
analyzed cellular responses from two Chinese rhesus mac-
aques previously infected with SIVmac239 and positive for
Mamu-B*039:01 by PCR-SSP, as detailed in the “Materials
and methods” section. Cellular immune responses in these
animals were evaluated using IFN-γ ELISPOT assay and
SIVmac239-derived peptides. Specifically, the PCSL data
were used to generate a predictive algorithm by standard
methods (Southwood et al. 2011). SIVmac239 sequences
scoring in the upper 3.0% range (n0100) were synthesized
and tested for in vitro MHC:peptide-binding affinity, 40 of
which bound Mamu-B*039:01 with an IC50 <500 nM.
These peptides were tested in IFN-γ ELISPOT assays using
cells from B*039:01 SIVmac239-infected animals to iden-
tify antigenic peptides (Table 2). Of the 40 SIV peptides
tested, 28 contained a glycine at the second position.
In terms of responses, a total of 8 of the 40 peptides
generated positive responses in at least one animal (see
Table 2). Specifically, ChRh 1 had three peptides with
average SFCs of >50. ChRh 2 had five peptides with an
average SFC of >50. Out of those eight responses, three
responses were induced by peptides which had a glycine at
position 2, indicating that these peptides are antigenic in the
setting of SIV infection.
Similarities of the B39 motif with the known H-2 D
d motif
Given the unusual preference of a glycine at the second
position of the MHC:peptide-binding motif, we investigated
whether other MHC molecules might also possess this par-
ticular characteristic. A thorough literature search revealed
that the only other known MHC class I molecules with a
reported preference of glycine at position 2 specificity were
Fig. 2 PSCL-derived matrix describing 9-mer binding to Mamu
B*039:01. The PSCL was tested for binding, the data analyzed, and
primary and secondary anchor positions defined, as described in the
“Materials and methods”. Values shown represent the average relative
binding (ARB) of the corresponding library relative to other pools with
the same fixed position. Values have been normalized to the optimal
residue at the corresponding position. SD indicates the standard devi-
ation between the ARB of pools at the same position. SF is the
specificity factor, calculated as described in the “Materials and meth-
ods” representing the ratio of the average binding of the entire library
to the average of pools at the indicated position. At the primary anchor
positions (SF > 2.4; blue shading), the most preferred residues, asso-
ciated with an ARB > 0.1 are highlighted by bold yellow font. Green
shading highlights secondary anchor positions. The library average
binding for Mamu-B*039:01 was 1,772 nM
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d MHC molecule (Corr et al. 1993; Li et al.
1998) and the Mamu-B*004 molecule (Dzuris et al. 2000).
Previously published data for H-2 D
d demonstrated a strong
requirement for G in position 2, along with proline (P) in
position 3 and hydrophobic residues at the C-terminus
(Fig. 3b) (Corr et al. 1993). Data for Mamu-B*004 likewise
showed a specificity for G in position 2, but displayed no
strict dependence on a C-terminal anchor (Dzuris et al.
2000).
Similarities of the Mamu-B*039:01 motif
with the Mamu-B*052:01 motif
Concurrently with these experiments, Mamu-B*052:01,
expressed in 8.4% Indian rhesus macaques, was also being
characterized. In a similar fashion to Mamu-B*039:01, we
eluted and sequenced peptides from this MHC molecule.
Sixteen peptides, consisting of 8-mers, 9-mers, and 10-mers,
were eluted and characterized. The most frequent size ob-
served was 8-mers, representing half of the endogenous
peptides identified. The other half was split equally between
9- and 10-mers at four peptides (25%) each. Similar to
Mamu-B*039:01, a dominant preference for G at position
2 was noted, as all peptides possessed this residue (Table 3).
The motif was further investigated by assessing the bind-
ing capacity using a PSCL (Fig. 4), as utilized in Mamu-
B*039:01 characterization. Analyzing the data as described
in the “Materials and methods” section, position 2 was
identified as a secondary anchor position, where G was
identified as a preferential, albeit not dominant residue. At
this point, it was noted that 8-mer peptides were the domi-
nant species for Mamu-B*052:01, comprising half of
a   Mamu-B*039:01
b  H-2 D
d
c  Mamu-B*052:01
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Fig. 3 Map of the a Mamu-B*039:01, b H-2 D
d,a n dc Mamu-
B*052:01 motif. Pictorial summary of the PSCL matrices, indicating
primary (in blue) and secondary (in green) anchor positions with
associated preferred and tolerated residues. Also represented are those
residues that are deleterious to binding at indicated positions (brown
font)
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based on 9-mers. To ensure thorough characterization of the
motif, and since an 8-mer PSCL was not available, we tested
a set of SAAS of an 8-mer ligand eluted from Mamu-
B*052:01 (sequence VGNVYVKF; IC50 7.4 nM). This
method identified position 2 as a primary anchor with a
dominant preference for G (Fig. 5), with every other
residue associated with a greater than two orders of magni-
tude reduction in binding capacity. Similarly to the case of
Mamu-B*039:01, the C-terminus was also identified as a
primary anchor position, with aromatic and aliphatic resi-
dues being preferred. Position 5 was identified as a domi-
nant secondary anchor position by definition. The summary
motif for Mamu-B*052:01 is shown in Fig. 3c.
Table 2 SIVmac239 peptides in
Mamu-B*039:01-positive
Chinese rhesus macaques
IFN-γ ELISPOT assays were
used to evaluate CD8+ T-cell
responses in two Mamu-
B*039:01-positive animals us-
ing Mamu-B*039:01 high-
affinity peptide binders. Peptides
derived from SIVmac239 were
tested for in vitro MHC:peptide-
binding affinity against Mamu-
B*039:01. SIVmac239 peptides
with binding affinity <500 nm
are shown. Peptide sequences in
bold font indicate a positive re-
sponse with a glycine at the
second position. Responses were
considered positive if the mean
of the number of SFC was more
than 50 spots per million cells
and the p≤0.05
Sequence Protein Position Mamu-B*039:01 IC50nM SFC’s 50 or greater
KAVATAPGL Tat 120 0.17
AGFLGLGPW Gag 432 0.25
LGIPHPAGL Pol 300 0.89
RGETYGRLL Nef open 24 1.0
RGFAAPQFS Pol 105 1.3
QGQYMNTPW Nef open 62 1.4
VAVHVASGF Pol 842 2.8
KGIGGNQEI Pol 747 4.4
QGWKGSPAI Pol 359 6.7
KGLGVNPTL Gag 336 8.0 ChRh 2
STYAVRITW Vif 83 8.8 ChRh 2
QGIRQVLFL Pol 761 9.1
KRGVFVLGF Env 524 15 ChRh 1
SGFIEAEVI Pol 848 15
RGVFVLGFL Env 525 19
KARLMAEAL Gag 360 36
KGWLSTYAV Vif 79 46
TVFYGVPAW Env 27 46
SGFMPKCSK Env 249 47
QGYWHLTPE Vif 70 56 ChRh 2
GGGNPLSAI Vpr 86 65
KGSPAIFQY Pol 362 66 ChRh 1
GGGNSSWPW Env 756 93
RGGRWILAI Env 858 99
GGFFRPWSM Pol 40 173
AGRWPITHL Pol 872 181
FGAEVVPGF Gag 166 190
LGMSLNFPI Pol 202 231
KGANFPGLA Vif 199 249
TGRQTALFL Pol 860 307
SLYNTVCVI Gag 77 314
IGFSTPEEK Pol 420 346
KHYWDAIRF Env 222 391
LGFLATAGS Env 533 415
KIVGGIGGF Pol 154 419 ChRh 2
PGIRYPKTF Nef open 163 444
LKNYMQLGK Gag 470 446 ChRh 2
RQLIRLLTW Env 774 474 ChRh 1
KEALAPVPI Gag 369 486
FGFNGTRAE Env 275 495
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between Mamu-B*039:01, H-2 D
d, and Mamu-B*052:01
Based on the crystal structures of MHC class I molecules
(Achour et al. 1998; Li et al. 1998; Madden 1995; Saper et
al. 1991), the MHC B pocket is hypothesized to interact
with the residue in position 2 of peptide ligands. Previously
(Sette et al. 2003), we had investigated similarities in posi-
tion 2 peptide-binding specificity between human and
mouse class I molecules and found that the similarities were
associated with very different B pocket structures, reflecting
convergent evolution. Given the similar and unusual prefer-
ences of Mamu-B*052:01, Mamu-B*039:01, and murine H-
2D
d for G in position 2, we next investigated whether a
common structural motif could be identified. We further
sought to determine if the shared specificity would be re-
flective of convergent evolution or the result of common
ancestry.
Accordingly, we analyzed the residues in positions 7, 9,
24, 34 45, 63, 66 67, 70, and 99 which compose the B
pocket of MHC class I molecules (Achour et al. 1998;L ie t
al. 1998; Madden 1995; Saper et al. 1991)o fM a m u -
B*039:01, H-2 D
d, and Mamu-B*052:01. Surprisingly, this
analysis revealed that all three alleles had very similar B
pocket structures (Table 4). Specifically, Mamu-B*039:01,
H-2 D
d, and Mamu-B*052:01 shared identical residues in
positions 7, 24, 34, 63, 66, and 67, where tyrosine (Y),
glutamic acid (E), valine (V), E, arginine (R), and alanine
(A) were found, respectively. With the exception of an A/Y
dichotomy in position 99, in which alanine is a small
nonpolar residue and tyrosine is a large polar aromatic,
variations at other positions were more conservative in
nature.
To determine if this structural motif was found in other
primate MHC class I alleles, we next compiled the
corresponding B pocket residues for all other available full
Mamu and HLA sequences. This analysis revealed that the
residues present in positions 24 (E) and 66 (R) of Mamu-
B*039:01, H2-D
d, and Mamu-B*052:01 were relatively
frequent in other macaque class I sequences (Table 4). In
macaques, R was present in position 66 in 13% and E in
position 24 in 15% of the 650 Mamu alleles analyzed; as a
tandem, they were found in an appreciable 5.7% of the
macaque sequences. As a whole, six Mamu alleles
(Mamu-B*004:01, Mamu-B*029:01:01, Mamu-
B*029:01:02, Mamu-B*029:02, Mamu-B*029:03, and
Mamu-B*032:01) matched the entire consensus sequence
shown in Table 4. By contrast, these residues, as a pair or
individually, were not found in any of the over 945 HLA
alleles analyzed (A in position 67, fairly common in mac-
aques, was also not found in any HLA sequence). These
differences in frequency are highly significant (p<0.0001 by
the Fisher’s exact test). These observations demonstrate that
the structural similarities associated with the specificity for
G in position 2 are not uncommon in macaques while this
type of peptide motif is not found in humans.
Taken together, the data in this section have defined a
common B pocket structural motif for alleles with specific-
ity for G in position 2. This structural motif was associated
with the presence of E in position 24 and R in position 66.
The presence of these residues in the corresponding posi-
tions is found in appreciable frequencies in macaques, at
both the phenotypic and genotypic levels, and absent in
humans.
Evolutionary origin of the pocket
We next examined whether the G2 structural motif in mac-
aques might be the result of convergent evolution of Mamu-
B*039:01 and Mamu-B*052:01 or a reflection of common
ancestry. For this analysis, we reconstructed a phylogenetic
tree for all available full-length Mamu allele sequences, five
common mouse alleles, and a set of common HLA alleles
(online resource 1). As expected, the mouse alleles are only
distantly related to the primate MHC alleles, confirming that
the emergence of the G2 motif in macaques and mice is the
result of convergent evolution. Mamu-B*039:01 and
Mamu-B*052:01, however, cluster together, suggesting that
the shared structural motif is due to a common ancestry. In
order to reveal the phylogenetic relationship between
Mamu-B alleles in more detail and independently of the
binding motif determining residues, we omitted 51 codons
encoding the residues that form the pockets in the peptide-
Table 3 Endogenous Mamu-B*052:01 ligands identified by MS/MS
sequencing analysis
Fraction Sequence Length Binding affinity (IC50 nM)
55 KGFSEEHNTW 10 0.77
54 AGAAALRPFA 10 11
59 TGYVATRW 8 41
59 KGFTDADNTW 10 1.5
59 SGGPKYEYRW 10 1.7
62 VGNVYVKF 8 7.4
62 LGRPDAEYW 9 5.2
62 RGPDAFRF 8 134
62 LGRPDEEYW 9 12
62 NGFQEETW 8 3.2
64 AGVWSQDKW 9 23
64 IGHRYIEVF 9 3.4
67 YGPKVDIW 8 12
72 HGVEFDFI 8 0.31
72 VGPRWMEW 8 1.3
72 EGPQYWEW 8 4.8
Immunogenetics (2012) 64:421–434 429binding groove. In the resulting phylogenetic tree, Mamu-
B*039:01 and Mamu-B*052:01 cluster together (Online
resource 2). Hence, within the same species, the shared
binding specificity of these alleles is the result of a common
ancestry, while between species, it is the result of conver-
gent evolution.
Discussion
In this study, we have described the peptide-binding speci-
ficity of the macaque MHC class I molecules, Mamu-
B*039:01, and Mamu-B*052:01. Both molecules were
found to preferentially bind peptides with glycine at the
second residue. Previously, Mamu-B*004 binding of a dom-
inant T-cell epitope was found to be dependent upon G in
position 2 (Dzuris et al. 2000). While more detailed analyses
of the specificity of this molecule were not undertaken due
to the unavailability of reagents, pocket analyses suggest
that this allele may also be a member of the supertype
delineated in the present study. Also, previous studies
revealed that the mouse MHC molecule H-2 D
d also has a
preference for glycine at the second position (Corr et al.
1993; Li et al. 1998). Strikingly, our analysis demonstrated
that this commonality hinges on convergent evolution inde-
pendently generating the same pocket structure in distantly
related MHC genes. Even more strikingly, this unique spec-
ificity is encoded in about 6% of macaque class I genes but
is totally absent in humans.
An analysis of all the residues comprising the MHC B
pocket of these macaque (Mamu) molecules, as well as the
mouse molecule D
d, revealed that they share very similar B
pocket structures. Together, the three molecules have iden-
tical residues in six of the ten positions hypothesized to form
the B pocket and largely chemically conserved residues at
the remaining positions. Most striking, however, is the
shared presence of E in position 24 and R in position 66.
These two residues, in these positions, are not found in any
of the almost 1,000 HLA alleles sequenced thus far.
Crystal structures of peptides bound to H-2 D
d (Achour et
al. 1998; Li et al. 1998) have suggested the presence of R in
position 66 likely drives the requirement for glycine in
Residue 1 2 3 4 5 6 7 8 9
A 0.170 0.111 0.230 0.137 0.262 0.152 0.371 0.146 0.011
C 0.171 0.023 0.072 0.128 0.195 0.104 0.158 0.064 0.010
D 0.102 0.114 0.346 0.145 0.201 0.160 0.414 0.099 0.008
E 0.081 0.172 0.253 0.028 0.126 0.044 0.091 0.015 0.024
F 0.113 0.073 1.000 0.412 0.667 1.000 1.000 1.000 0.538
G 0.092 1.000 0.587 0.172 0.144 0.084 0.239 0.148 0.017
H 0.125 0.080 0.333 0.191 0.256 0.127 0.570 0.056 0.006
I 0.158 0.155 0.479 0.144 0.543 0.176 0.227 0.052 0.075
K 0.274 0.039 0.049 0.157 0.053 0.067 0.039 0.065 0.004
L 0.144 0.038 0.209 1.000 0.315 0.066 0.321 0.235 0.032
M 1.000 0.093 0.495 0.359 0.200 0.136 0.268 0.160 0.014
N 0.079 0.125 0.289 0.217 0.031 0.100 0.190 0.076 0.012
P 0.043 0.056 0.316 0.203 0.222 0.144 0.262 0.132 0.002
Q 0.089 0.125 0.210 0.159 0.348 0.126 0.160 0.156 0.008
R 0.604 0.063 0.122 0.229 0.145 0.107 0.078 0.103 0.009
S 0.254 0.080 0.387 0.181 1.000 0.132 0.370 0.090 0.006
T 0.137 0.079 0.311 0.133 0.396 0.184 0.168 0.130 0.007
V 0.152 0.034 0.287 0.064 0.248 0.185 0.217 0.145 0.011
W 0.135 0.060 0.454 0.314 0.199 0.919 0.340 0.218 1.000
Y 0.146 0.137 0.449 0.652 0.328 0.568 0.376 0.305 0.321
Geomean 0.15 0.090 0.28 0.19 0.23 0.15 0.23 0.12 0.020
SD 2.0 2.2 2.0 2.1 2.2 2.2 2.1 2.3 5.2
SF 0.88 1.53 0.47 0.70 0.59 0.86 0.57 1.13 6.93
Position
Fig. 4 PSCL-derived matrix describing 9-mer binding to Mamu
B*052:01. The PSCL was tested for binding, the data analyzed, and
primary and secondary anchor positions defined, as described in the
“Materials and methods”. Values shown represent the average relative
binding (ARB) of the corresponding library relative to other pools with
the same fixed position. Values have been normalized to the optimal
residue at the corresponding position. SD indicates the standard devi-
ation between the ARB of pools at the same position. SF is the
specificity factor, calculated as described in the “Materials and meth-
ods” representing the ratio of the average binding of the entire library
to the average of pools at the indicated position. At the primary anchor
positions (SF > 2.4; blue shading), the most preferred residues, asso-
ciated with an ARB > 0.1 are highlighted by bold yellow font. Green
shading highlights secondary anchor positions. The library average
binding for Mamu-B*052:01 was 1,422 nM
430 Immunogenetics (2012) 64:421–434position 2 of the corresponding peptide ligands. In both
reported structures, the arginine at position 66 is shown
to point down into the binding groove, where it forms
salt bridges with E24 and E63. Contact between R66
and Y45 is also noted. Together, these contacts result in
a narrowing of the B pocket, such that the presence of
any residue except G in position 2 would likely result in
steric clashes with R66.
Table 4 Alignment of B pocket residues of alleles with a preference for G2 reveals a unique structural motif
Alignment of B pocket residues
System Region Allele B pocket position/residue
7 9 24 34 45 63 66 67 70 99
H-2 – Dd Y V E V Y E R A N A
Mamu Chinese B*039:01 Y T E V L E R A T Y
Mamu Indian B*052:01 Y S E V M E R A N Y
Consensus sequence Y VTS E V YLM E R A NT YA
Frequency of consensus residue(s)
System No. of alleles Full pocket match B pocket position
a
7 9 24 34 45 63 66 67 70 99
Mamu 650 8 1.0 0.32 0.15 0.88 0.65 0.39 0.13 0.47 0.27 0.74
HLA 945 0 1.0 0.11 0 1.0 0.46 0.58 00 0.50 0.91
Bold font highlights positions where the consensus sequence is found in less than one third of the corresponding MHC alleles
Residue 1 2 345678
A 0.040 0.007 0.246 0.045 0.175 0.587 0.955 0.032
C 1.000 0.003 0.067 0.032 0.015 0.602 0.018 0.020
D 0.004 0.003 0.553 0.037 0.010 0.147 0.011 0.001
E 0.004 0.003 0.280 0.023 0.020 0.713 0.007 0.001
F 0.011 0.002 0.013 0.039 0.084 0.131 0.012 1.000
G 0.005 1.000 0.113 0.021 0.005 0.403 1.000 0.001
H 0.013 0.009 0.609 0.026 0.017 0.419 0.037 0.000
I 0.009 0.000 0.100 0.005 0.002 0.147 0.002 0.358
K 0.052 0.000 0.033 0.022 0.000 0.041 0.080 0.005
L 0.008 0.000 0.121 0.009 0.010 0.307 0.001 0.114
M 0.001 0.001 1.000 0.195 0.471 0.201 0.001 0.069
N 0.009 0.001 0.978 0.023 0.008 0.524 0.876 0.001
P 0.001 0.001 0.780 0.011 0.000 0.775 0.011 0.000
Q 0.065 0.002 0.294 0.036 0.027 0.586 1.000 0.000
R 0.010 0.000 0.044 0.005 0.000 0.551 1.000 0.000
S 0.009 0.002 0.795 0.081 0.008 0.510 0.015 0.001
T 0.003 0.001 0.620 1.000 0.004 0.316 0.028 0.001
V 0.080 0.001 0.094 0.083 0.180 0.983 0.001 0.006
W 0.002 0.001 0.088 0.017 1.000 0.887 0.008 0.350
Y 0.007 0.001 0.098 0.009 0.324 1.000 0.457 0.084
Geomean 0.010 <0.001 0.19 0.030 0.010 0.39 0.030 0.010
SD 5.4 6.0 3.5 3.5 12.8 2.3 11.8 14.3
SF 2.4 13.8 0.13 0.83 1.7 0.060 0.74 3.6
Position
Fig. 5 SAAS-derived matrix describing 8-mer binding to Mamu-
B*052:01. A panel of single amino acid substitution analogs of the
Mamu-B*052:01 binding 7.4 (sequence VGNVYVKF) was tested for
binding, and the data analyzed, as described for the PSCL in the
“Materials and methods”. Because of the larger SD in the panels of
SAAS, compared to PSCL, more stringent criteria to define primary
and secondary anchor positions have been utilized, as also described in
the “Materials and methods”. At the primary anchor positions (SF >
3.5; blue shading), the most preferred residues, associated with an
ARB > 0.1 are highlighted by bold yellow font. Green shading high-
lights secondary anchor positions. The library average binding for
Mamu-B*052:01 was 18.0 nM
Immunogenetics (2012) 64:421–434 431Since B*039:01 and B*052:01 share the E24-E63-R66
structural motif with H-2 D
d, it is reasonable to assume that
a similar narrowing of the B pocket is present and drives the
preference for G in position 2 of their ligands. The observa-
tion that both Mamu-B*039:01 and -B*052:01 can bind
ligands with residues other than G in position 2, albeit with
lower avidity, does suggest that there may be correspond-
ingly less hindrance in their B pockets than is the case
for H-2 D
d. This observation may be due to the fact
that these two Mamu molecules have, respectively, L
and methionine (M) in position 45, located on the floor of
the B pocket. These residues occupy less volume than the
corresponding Ypresent in H-2 D
d and accordingly result in a
B pocket with more space available to accommodate larger
residues.
Unlike Mamu-B*039:01 and -B*052:01, H-2 D
d has a
very strong preference for proline in position 3 (Corr et al.
1993). This specificity is hypothesized to be driven by the
presence of a narrow hydrophobic ridge, formed by a pair of
tryptophans in positions 97 and 114, that splits the D pocket
and reduces its depth and volume (Achour et al. 1998;L ie t
al. 1998). Besides providing stabilizing interactions with the
resulting small pocket, the proline may allow the peptide
conformation necessary to ascend the wall formed by the
tryptophan pair. Neither Mamu molecule studied here con-
tains the tryptophan pair present in the murine D
d molecule,
and therefore, the corresponding hydrophobic ridge is likely
not present, thus liberating Mamu-B*039:01 and B*052:01
from a similar constraint in position 3.
Given the absence of these particular amino acid prefer-
ences in HLA sequences, we were interested in how non-
human primate sequences and a mouse sequence have
evolved. We analyzed macaque and mouse sequences from
a phylogenetic perspective. These analyses revealed that
within the same species, the evolution of these sequences
is the result of common ancestry, while between species, it is
the result of convergent evolution. It is therefore interesting
to speculate why these sequences are absent in humans. It is
possible that HLA sequences have not evolved to develop
this particular motif because the evolutionary pressure lead-
ing to the origination of this motif was absent or that the
expression of such specificity might be for some reason
detrimental in humans. These binding specificities may be
associated with disease susceptibility or autoimmunity. A
specific event, such as a selective sweep (de Groot et al.
2008; de Groot et al. 2002) or bottleneck effect can also be
considered as a possible explanation.
We cannot speculate on the biological significance of the
peptide-binding motif elucidated herein for mice and mac-
aques. Besides not being found in humans, the hallmark
E24-R66 structural motif has also not been reported to date
in most other nonhuman primates, including gorillas, chim-
panzees, orangutans, olive baboons, pigtail macaques, and
crab-eating macaques, as well as rats, sheep, and canines
(Robinson et al. 2010).
On the other hand, it is found in a few cases in African
green monkeys and swine and in several instances in cattle.
The disparate phylogenetic relationships between the spe-
cies that do show the motif strengthen the idea that it is the
result of convergent evolution. At this time, however, we
cannot speculate as to the specific mechanism(s) driving
generation and maintenance of this motif, although the
MHC-I richness, as seen in rhesus macaques, African green
monkeys, rodents, and swine, might play a role in maintain-
ing some “specialized” peptide-binding specificity.
In summary, herein we describe a new supertype motif
that encompasses MHC molecules that preferentially bind
peptides containing the glycine residue at the second posi-
tion. These findings suggest that novel evolutionary mech-
anisms result in this particular MHC peptide-binding motif
originating independently in nonhuman primates and mu-
rine species, but being totally absent in human MHC
molecules.
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